Men who use aspirin or other blood thinners after treatment for prostate cancer have a substantially lower risk of dying or seeing the cancer spread to another organ, new research shows. In a study of nearly 5,300 men with prostate cancer, only 4 percent of those taking blood-thinning medications such as aspirin had died from a recurrence of their cancer after 10 years, versus 10 percent of those not taking the medication — reducing the risk of dying from cancer by more than half.
Aspirin use may benefit prostate cancer patients. Blood thinners interfere with blood-clotting mechanisms, said Kevin Choe, M.D., a radiation oncologist at the University of Texas Southwestern Medical School and lead author of the study. "There is good evidence from laboratory studies which suggests that these clotting mechanisms play an important role in cancer growth and spread as well," Choe said.